MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

25.00 +0.70 (+2.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
The 7 Best Growth Stocks to Buy for February 2023 ↗
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
News headline image
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
News headline image
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed? ↗
Things aren't as bad as they might seem. 
Via The Motley Fool
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 Today ↗
 
Via Benzinga
Analyst Expectations for Catalyst Pharmaceuticals's Future ↗
 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback ↗
Catalyst is adding to its portfolio with a $160 million deal. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
News headline image
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The... 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its... 
Via Benzinga
News headline image
Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗
Investors seem intent on leaving last week's losses behind, as earnings season heats up. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Jumps Over 300 Points; Crude Oil Up 1% ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500... 
Via Benzinga
News headline image
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product ↗
 
Via Benzinga
News headline image
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views ↗
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday. 
Via Benzinga
News headline image
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product ↗
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone. 
Via Investor's Business Daily
News headline image
Why Catalyst Pharmaceuticals Shares Are Moving ↗
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13.46% to $18.00 Monday morning after Teva Pharmaceuticals stated it plans to sell a generic version of Catalyst's FIRDAPSE in... 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise. 
Via MarketBeat
News headline image
IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
IDEXX Laboratories sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
News headline image
Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8 ↗
For a growth-oriented choice for the new year, I'm going with under-the-radar company, Catalyst Pharmaceuticals. Let's take a look at the company's fundamentals, technicals, and institutional support... 
Via Talk Markets
News headline image
Top Picks For 2023: Catalyst Pharmaceuticals ↗
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top... 
Via Talk Markets
News headline image
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's ↗
It's practically printing cash, and even more is on the way. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story